Or register here
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

Sickle Cell Trait and Risk of Cognitive Impairment in African-Americans: The Regards Cohort

key information

source: EClinicalMedicine

year: 2019

authors: Cahill CR, Leach JM, McClure LA, Irvin MR, Zakai NA, Naik R, Unverzagt F, Wadley VG, Hyacinth HI, Manly J, Judd SE, Winkler C, Cushman M

summary/abstract:

Background:
Sickle cell anemia may be associated with cognitive dysfunction, and some complications of sickle cell anemia might affect those with sickle cell trait (SCT), so we hypothesized that SCT is a risk factor for cognitive impairment.

Methods:

The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study enrolled a national cohort of 30,239 white and black Americans from 2003 to 7, who are followed every 6 months. Baseline and annual global cognitive function testing used the Six-Item Screener (SIS), a validated instrument (scores range 0–6; ≤4 indicates cognitive impairment). Participants with baseline cognitive impairment and whites were excluded. Logistic regression was used to calculate the association of SCT with incident cognitive impairment, adjusted for risk factors. Linear mixed models assessed multivariable-adjusted change in test scores on a biennially administered 3-test battery measuring learning, memory, and semantic and phonemic fluency.

Findings:

Among 7743 participants followed for a median of 7•1 years, 85 of 583 participants with SCT (14•6%) developed incident cognitive impairment compared to 902 of 7160 (12•6%) without SCT. In univariate analysis, the odds ratio (OR) of incident cognitive impairment was 1•18 (95% CI: 0•93, 1•51) for those with SCT vs. those without. Adjustment did not impact the OR. There was no difference in change on 3-test battery scores by SCT status (all p N 0•11).

Interpretation:

In this prospective cohort study of black Americans, SCT was not associated with incident cognitive impairment or decline in test scores of learning, memory and executive function.

FUNDING:
National Institutes of Health, American Society of Hematology.

organization: University of Vermont, USA; University of Alabama at Birmingham, USA; Drexel University, USA; Johns Hopkins University, USA; Indiana University School of Medicine, USA; Emory University, USA; Columbia University Medical Center, USA, National Institutes of Health, USA

DOI: 10.1016/j.eclinm.2019.05.003

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close